BRII-5395
/ Brii Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
BRII-5395, an HBV antigen–targeted LNP-mRNA vaccine, induces potent antitumor immunity alone and in combination with anti–PD-1 in a murine tumor model
(SITC 2026)
- No abstract available
Combination therapy • Preclinical • Oncology
1 to 1
Of
1
Go to page
1